Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201747 | 1.00 | CYP3A4 (0.47) | CYP3A4CTSBPPP3CBMCL1 | |
| SCHEMBL13219488 | 0.92 | CYP3A4 (0.41) | CYP3A4CTSBPPP3CB | |
| SCHEMBL13201751 | 0.91 | CYP3A4 (0.47) | CYP3A4CTSBPPP3CB | |
| SCHEMBL13201772 | 0.90 | CYP3A4 (0.45) | CYP3A4CTSBPPP3CB | |
| SCHEMBL13201745 | 0.89 | CTSB (0.48) | CYP3A4CTSBPPP3CBMCL1 | |
| SCHEMBL13201741 | 0.89 | CTSB (0.44) | CYP3A4CTSBPPP3CBMCL1 | |
| SCHEMBL13385203 | 0.89 | CYP3A4 (0.42) | CYP3A4CTSBPPP3CBMCL1 | |
| SCHEMBL13910766 | 0.88 | CYP3A4 (0.43) | CYP3A4CTSBPPP3CB | |
| SCHEMBL8277280 | 0.86 | CTSB (0.49) | CYP3A4CTSBPPP3CB | |
| SCHEMBL13365333 | 0.85 | CYP3A4 (0.44) | CYP3A4CTSBPPP3CBMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-7767818-B2 | Hepatitis C inhibitor dipeptide analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511157-B2 | racemic mixtures, stereoisomers or optical isomers, useful as protease inhibitors; viricides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156822-A1 | Hepatitis C Inhibitor Dipeptide Analogs | DPP3, CTSC, ANPEP | CYP3A4 1024/4885CTSB 430/4885PPP3CB 893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.